Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that recently, a new drug application of Cisplatin Injection (the "New Drug"), a drug independently developed by Jisimei (Wuhan) Pharmaceutical Co., Ltd. (Ji Si Mei (Wu Han) Zhi Yao Xian Gong Si), a subsidiary of Shanghai Fosun Pharmaceutical (Group") Co., Ltd. (Shang Hai Fu Xing Yi Yao (Ji Tuan)Gu Fen You Xian Gong Si) (the "Company" and, together with its subsidiaries/units, the "Group"), has been accepted by the National Medical Products Administration. General information and research progress of the New Drug. The New Drug is a chemical drug independently developed by the Group and is intended to be used for (1) in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures, (2) as a single agent, being indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy, or in established combination therapy with otherapproved chemotherapeutic agents in patient with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherape therapeutic procedures (an established combination consists of Cisplatin In injection and cyclophosphamide), (3) indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as.

surgery and/or radiotherapy. As at the date of this announcement, the cisplatin preparations of the same kind that have been launched in China (hereinafter excluding Hong Kong, Macau and Taiwan region for the purpose of this announcement, the same applies below) mainly include NUOXIN (Nuo Xin) of Jiangsu Hansoh Pharmaceutical Group Company Limited (Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si), Cisplatin for Injection of Qilu Pharmaceutical Co., Ltd. (Qi Lu Zhi Yao Xian GongSi) and LIAIKANG (Li Ai Kang) of Yunnan Phytopharmaceutical Co., Ltd. (Yun Nan Zhi Wu Yao Xian Gong Si). According to the latest data of IQVIA CHPA1, the sales of cisplatin preparations of the similar kind in China amounted to approximately RMB124 million in 2022.

As of July 2023, the Group's accumulative research and development investment for the New Drug at current stage is approximately RMB 2.27 million (unaudited). The New Drug is subject to, among others, the passing of the GMP compliance inspection and the drug registration approval before it can be commercialized. This acceptance of the drug registration application will not have a material impact on the current results of the Group.

Due to the industry characteristics inherent to pharmaceutical products, the specific sales performance of the Company is expected to be in 2022.